Skip to main content
. 2015 Jan 27;19(3):664–675. doi: 10.1111/jcmm.12382

Fig 2.

Fig 2

IL12 pDNA can confer an antitumour immune response. (A) In squamous cell carcinoma, ECGT with IL12 pDNA and a chemotherapeutic induces tumour regression equally compared to IL12 pDNA alone plus electroporation, but the tumour growth resumes by day 21 after treatment (n + 5 for IL12 pDNA alone and n + 20 for ECGT). (B) In acanthomatous ameloblastoma, IL12 pDNA alone plus electroporation appears more effective than ECGT with IL12 pDNA and a chemotherapeutic, although the difference is not significant (n + 4). (C) In Sarcomas, IL12 pDNA alone plus electroporation (n + 2) appears to stabilize the tumour volume while ECGT with IL12 pDNA and a chemotherapeutic (n + 9) cannot inhibit tumour growth; however, the low sample size of IL12 pDNA prohibits statistical analysis. (D) SCC tumours located anywhere except the nasal planum (non-NP SCC, n + 20) respond to ECGT with an average 30% tumour reduction in only 21 days, but nasal planum SCC tumours (NP SCC, n + 8) do not respond to ECGT. (E) A non-treated metastatic lymph node SCC tumour steadily regressed after two treatments in the initial dorsal carpus tumours on days 0 and 7. At 96 days after the treatments in the dorsal carpus tumours, progression of the metastatic nodule was noted. X denotes surgical removal of the metastatic tumour. Error bars represent SEM.